|
(11) | EP 1 371 983 B1 |
(12) | EUROPEAN PATENT SPECIFICATION |
|
|
(54) |
Immunoassay, reagent for immunoassay, and production method of the same Immuntestverfahren, Reagenz für Immuntestverfahren und Verfahren zu dessen Herstellung Dosage immunologique, réactif pour le dosage immunologique et méthode de production |
|
|
|||||||||||||||||||||||||||||||
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). |
Background of the Invention
Field of the Invention
SUMMARY OF THE INVENTION
preparing a carrier on which an antigen or antibody corresponding to an antibody or antigen in said specimen respectively is immobilized;
mixing said carrier with said specimen; and
assaying the level of an immunological agglutination reaction caused by said mixing step,
wherein said antigen or antibody immobilized on said carrier is bound to said carrier via an amino acid sequence capable of binding to said carrier.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
(Examples)
(Reference example 1)
Obtainment of antigen protein to Hepatitis C virus antibody
(Example 1)
Obtainment of amino acid sequence capable of binding to copper phthalocyanine
(1) Copper phthalocyanine (α form, Tokyo Kasei Kogyo Co., Ltd.) was suspended in a TBS buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl) containing 0.1% Tween-20, at a concentration of 5 mg/ml. 10 µl of the suspension was put in an Eppendorf tube, and 990 µl of a TBST buffer (a TBS buffer + 0.1% Tween-20) was further added thereto for dilution.
(2) Approximately 4 × 1010 pfu of Ph. D. -12 phage display peptide library (New England BioLabs) was added to the tube, and was left to stand at 25°C for 10 minutes.
(3) The tube was subjected to centrifugation (20,630 × g, 5 minutes). Thereafter, the supernatant was discarded, and the pigment was recovered as a precipitate. The recovered pigment was suspended in a TBST buffer again, and washed 10 times by repeating centrifugation.
(4) 100 µl of an elution buffer (0.2 M Glycine-HCl, pH 2.2, 1 mg/ml BSA) was added thereto and the suspension was left to stand for 1 minute, and then centrifuged (20,630 × g, 5 minutes). The obtained supernatant was transferred into another Eppendorf tube, to which 15 µl of 1 M Tris-HCl (pH 9.1) was added for neutralization. Thus the eluted phages were obtained.
(5) The eluted phages were used to infect E. coli ER2537 (New England BioLabs) cells in its early logarithmic growth phase were infected to be amplified therein. Culture was carried out at 37°C for 4.5 hours. Thereafter, the amplified phages were separated from the cells by centrifugation, and then purified by precipitation with polyethylene glycol. The thus amplified and purified phages were then suspended in a TBS buffer, and the titer was determined by using an appropriate dilution series to infect E. coli cells.
(6) The above steps (1) to (5) were repeated three times using amplified phages. However, the concentration of Tween-20 in the TBS buffer was increased to 0.5% to establish more strict washing conditions.
Titer of phage eluted in each cycle | |||||
Stock solution (A) | Binding tocontrol (B) | Binding to phthalocyanine (C) | C/A | C/B | |
1st cycle | 4.0×1011 | 1.2×106 | 3.0×10-6 | ||
2nd cycle | 1.6×1011 | 1.1×105 | 1.7×105 | 1.1×10-5 | 1 |
3rd cycle | 2.0×1011 | 1.6×105 | 3.0×108 | 1.5×10-3 | 1800 |
4th cycle | 1.7×1011 | 2.7×106 | 5.3×109 | 3.1×10-2 | 2000 |
(Units of A, B and C: pfu/ml) |
Determined amino acid sequences and their frequencies | ||
Determined amino acid sequences | Numbers (A) | Frequencies (A/36) |
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1) | 6 | 0.17 |
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2) | 6 | 0.17 |
Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3) | 4 | 0.11 |
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ ID NO 4) | 3 | 0.08 |
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5) | 3 | 0.08 |
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6) | 3 | 0.08 |
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7) | 3 | 0.08 |
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-Tyr-Gly-Val (SEQ ID NO 8) | 1 | 0.02 |
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-Gln (SEQ ID NO 9) | 1 | 0.02 |
Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 10) | 1 | 0.02 |
Lys-Va1-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11) | 1 | 0.02 |
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-Pro-Trp (SEQ ID NO 12) | 1 | 0.02 |
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-Thr-Ser-Val (SEQ ID NO 13) | 1 | 0.02 |
Thr-Leu-Pro-Ser-Pro-Leu-Ala-Leu-Leu-Thr-Val-His (SEQ ID NO 14) | 1 | 0.02 |
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-Val (SEQ ID NO 15) | 1 | 0.02 |
(Example 2)
Obtainment of amino acid sequence capable of binding to carbon black
Titer of phage eluted in each cycle | |||||
Stock solution (A) | Binding to control (B) | Binding to carbon black (C) | C/A | C/B | |
1st cycle, | 4.0×1011 | 8.9×106 | 2.2×10-5 | ||
2nd cycle | 1.6×1011 | 1.1×105 | 3.8×106 | 2.4×10-5 | 35 |
3rd cycle | 2.0×1011 | 1.6×105 | 6.0×106 | 3.0×10-5 | 40 |
4th cycle | 1.7×1011 | 1.1×106 | 1.5×108 | 8.8×10-4 | 140 |
5th cycle | 1.9×1011 | 2.0×106 | 2.7×109 | 1.4×10-2 | 1400 |
(Units of A, B and C: pfu/ml) |
Determined amino acid sequences and their frequencies | ||
Determined amino acid sequences | Numbers (2) | Frequencies (A/38) |
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser (SEQ ID NO 16) | 4 | 0.10 |
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17) | 3 | 0.08 |
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18) | 2 | 0.05 |
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19) | 2 | 0.05 |
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20) | 2 | 0.05 |
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21) | 2 | 0.05 |
Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val (SEQ ID NO 22) | 2 | 0.05 |
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23) | 2 | 0.05 |
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24) | 2 | 0.05 |
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SEQ ID NO 25) | 2 | 0.05 |
Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26) | 1 | 0.03 |
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27) | 1 | 0.03 |
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28) | 1 | 0.03 |
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO 29) | 1 | 0.03 |
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-Val (SEQ ID NO 30) | 1 | 0.03 |
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31) | 1 | 0.03 |
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32) | 1 | 0.03 |
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-Arg-Ser-Val (SEQ ID NO 33) | 1 | 0.03 |
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34) | 1 | 0.03 |
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35) | 1 | 0.03 |
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36) | 1 | 0.03 |
Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37) | 1 | 0.03 |
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38) | 1 | 0.03 |
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39) | 1 | 0.03 |
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40) | 1 | 0.03 |
(Example 3)
Production of antigen protein capable of binding to copper phthalocyanine
Synthesized DNA used in expression of each amino acid sequence | |
Amino acid sequence No. | Nucleotide sequence of synthesized DNA |
1 | |
2 | |
3 | |
4 | |
5 | |
6 | |
7 | |
8 | |
9 | |
10 | |
11 | |
12 | |
13 | |
14 | |
15 |
(SEQ ID NO:43-72) |
(Example 4)
Production of antigen protein capable of binding to carbon black
Synthesized DNA sets used in expression of each amino acid sequence | |
Amino acid sequence No. | Nucleotide sequence of synthesized DNA |
16 | |
17 | |
18 | |
19 | |
20 | |
21 | |
22 | |
23 | |
24 | |
25 | |
26 | |
27 | |
28 | |
29 | |
30 | |
31 | |
32 | |
33 | |
34 | |
35 | |
36 | |
37 | |
38 | |
39 | |
40 |
(SEQ ID NO:73-122) |
(Example 5)
Production of antigen protein capable of binding to copper phthalocyanine
(Example 6)
Production of antigen protein capable of binding to carbon black
(Comparative example 1)
Production of antigen protein
(Example 7)
Immobilization of antigen protein on copper phthalocyanine particle
Evaluation of binding ability of enzyme to copper phthalocyanine | ||
Amino acid sequence No. | Amount of protein (µg) | |
Example 3 | 1 | 6 |
Example 3 | 2 | 6 |
Example 3 | 3 | 5 |
Example 3 | 4 | 5 |
Example 3 | 5 | 5 |
Example 3 | 6 | 5 |
Example 3 | 7 | 5 |
Example 3 | 8 | 5 |
Example 3 | 9 | 5 |
Example 3 | 10 | 5 |
Example 3 | 11 | 5 |
Example 3 | 12 | 5 |
Example 3 | 13 | 5 |
Example 3 | 14 | 4 |
Example 3 | 15 | 4 |
Example 5 | 41 | 11 |
Comparative example 1 | - | 1 |
(Example 8)
Immobilization of antigen protein on carbon black article
Evaluation of binding ability of enzyme to carbon black | ||
Amino acid sequence No. | Amount of protein (µg) | |
Example 4 | 16 | 6 |
Example 4 | 17 | 6 |
Example 4 | 18 | 5 |
Example 4 | 19 | 5 |
Example 4 | 20 | 5 |
Example 4 | 21 | 5 |
Example 4 | 22 | 5 |
Example 4 | 23 | 5 |
Example 4 | 24 | 5 |
Example 4 | 25 | 5 |
Example 4 | 26 | 5 |
Example 4 | 27 | 5 |
Example 4 | 28 | 5 |
Example 4 | 29 | 4 |
Example 4 | 30 | 4 |
Example 4 | 31 | 4 |
Example 4 | 32 | 4 |
Example 4 | 33 | 4 |
Example 4 | 34 | 4 |
Example 4 | 35 | 4 |
Example 4 | 36 | 4 |
Example 4 | 37 | 4 |
Example 4 | 38 | 4 |
Example 4 | 39 | 4 |
Example 4 | 30 | 4 |
Example 6 | 42 | 15 |
Comparative example 1 | - | 1 |
(Example 9)
Assay of HCV antibody by immunoagglutination assay
Assay results of serum of HCV antibody positive patients | |||||
Amino acid sequence No. | Dilution of serum (times) | ||||
10,000 | 25,000 | 50,000 | 100,000 | ||
Example 7 | 1 | + | + | + | - |
2 | + | + | + | - | |
3 | + | + | + | - | |
4 | + | + | + | - | |
5 | + | + | + | - | |
6 | + | + | + | - | |
7 | + | + | + | - | |
8 | + | + | + | - | |
9 | + | + | + | - | |
10 | + | + | + | - | |
11 | + | + | + | - | |
12 | + | + | + | - | |
13 | + | + | + | - | |
14 | + | + | + | - | |
15 | + | + | + | - | |
41 | + | + | + | - | |
Commercially available product | - | + | + | - | - |
(In the table, + means that agglutination is observed, and - means that no agglutination is observed.) |
Assay results of serum of Hepatitis C virus antibody positive patients | |||||
Amino acid sequence No. | Dilution of serum (times) | ||||
10,000 | 25,000 | 50,000 | 100,000 | ||
Example 8 | 16 | + | + | + | - |
17 | + | + | + | - | |
18 | + | + | + | - | |
19 | + | + | + | - | |
20 | + | + | + | - | |
21 | + | + | + | - | |
22 | + | + | + | - | |
23 | + | + | + | - | |
24 | + | + | + | - | |
25 | + | + | + | - | |
26 | + | + | + | - | |
27 | + | + | + | - | |
28 | + | + | + | - | |
29 | + | + | + | - | |
30 | + | + | + | - | |
31 | + | + | + | - | |
32 | + | + | + | - | |
33 | + | + | + | - | |
34 | + | + | + | - | |
35 | + | + | + | - | |
36 | + | + | + | - | |
37 | + | + | + | - | |
38 | + | + | + | - | |
39 | + | + | + | - | |
40 | + | + | + | - | |
42 | + | + | + | - | |
Commercially available product | - | + | + | - | - |
(In the table, + means that agglutination is observed, and - means that no agglutination is observed.) |
SEQUENCE LISTING
<110> CANON KABUSHIKI KAISHA
<120> Immunoassay, reagent for immunoassay, and production method of the same
<130> CFO17318
<150> JP P2002-173027
<151> 2002-06-13
<150> JP P2003-127099
<151> 2003-05-02
<160> 129
<170> PatentIn version 3.1
<210> 1
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 1
<210> 2
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 2
<210> 3
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 3
<210> 4
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 4
<210> 5
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 5
<210> 6
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 6
<210> 7
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 7
<210> 8
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 8
<210> 9
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 9
<210> 10
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 10
<210> 11
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 11
<210> 12
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 12
<210> 13
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 13
<210> 14
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 14
<210> 15
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 15
<210> 16
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 16
<210> 17
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 17
<210> 18
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 18
<210> 19
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 19
<210> 20
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 20
<210> 21
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 21
<210> 22
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 22
<210> 23
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 23
<210> 24
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 24
<210> 25
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 25
<210> 26
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 26
<210> 27
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 27
<210> 28
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 28
<210> 29
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 29
<210> 30
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 30
<210> 31
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 31
<210> 32
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 32
<210> 33
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 33
<210> 34
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 34
<210> 35
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 35
<210> 36
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 36
<210> 37
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 37
<210> 38
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 38
<210> 39
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 39
<210> 40
<211> 12
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 40
<210> 41
<211> 32
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 41
<210> 42
<211> 32
<212> PRT
<213> Artificial
<220>
<223> binding peptide
<400> 42
<210> 43
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 43
gatccaaata tgatagccgt catctgcata cccatagcca tgagct 46
<210> 44
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 43
<400> 44
catggctatg ggtatgcaga tgacggctat catatttg 38
<210> 45
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 45
gatccccgaa ccgtctgggc cgtcgtccgg tgcgttggga agagct 46
<210> 46
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 45
<400> 46
cttcccaacg caccggacga cggcccagac ggttcggg 38
<210> 47
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 47
gatccaaatg ctgctattat gatcatagcc atgcgctgag cgagct 46
<210> 48
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 47
<400> 48
cgctcagcgc atggctatga tcataatagc agcatttg 38
<210> 49
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 49
gatccgaata tctgagcgcg attgtggcgg gcccgtggcc ggagct 46
<210> 50
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 49
<400> 50
ccggccacgg gcccgccaca atcgcgctca gatattcg 38
<210> 51
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 51
gatccaaact gtggattctg gaaccgaccg tgaccccgac cgagct 46
<210> 52
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 51
<400> 52
cggtcggggt cacggtcggt tccagaatcc acagtttg 38
<210> 53
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 53
gatcccagag caacctgaaa gtgattccga gctggtggtt tgagct 46
<210> 54
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 53
<400> 54
caaaccacca gctcggaatc actttcaggt tgctctgg 38
<210> 55
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 55
gatcctggat tccgccgcag tggagccgtc tgattgaacc ggagct 46
<210> 56
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 55
<400> 56
ccggttcaat cagacggctc cactgcggcg gaatccag 38
<210> 57
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 57
gatccgatca tccgcaggcg aaaccgaact ggtatggcgt ggagct 46
<210> 58
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 57
<400> 58
ccacgccata ccagttcggt ttcgcctgcg gatgatcg 38
<210> 59
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 59
gatccggcct gccgccgtat agcccgcatc gtctggcgca ggagct 46
<210> 60
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 59
<400> 60
cctgcgccag acgatgcggg ctatacggcg gcaggccg 38
<210> 61
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 61
gatccaaact gaccacccag tatatggcgc gtagcagcag cgagct 46
<210> 62
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 61
<400> 62
cgctgctgct acgcgccata tactgggtgg tcagtttg 38
<210> 63
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 63
gatccaaagt gtggatgctg ccgccgctgc cgcaggcgac cgagct 46
<210> 64
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 63
<400> 64
cggtcgcctg cggcagcggc ggcagcatcc acactttg 38
<210> 65
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 65
gatccaacgt gaccagcacc gcgtttattg ataccccgtg ggagct 46
<210> 66
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 65
<400> 66
cccacggggt atcaataaac gcggtgctgg tcacgttg 38
<210> 67
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 67
gatcccgtct gaacctggat attattgcgg tgaccagcgt ggagct 46
<210> 68
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 67
<400> 68
ccacgctggt caccgcaata atatccaggt tcagacgg 38
<210> 69
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 69
gatccaccct gccgagcccg ctggcgctgc tgaccgtgca tgagct 46
<210> 70
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 69
<400> 70
catgcacggt cagcagcgcc agcgggctcg gcagggtg 38
<210> 71
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 71
gatccaccaa ccgtcataac ccgcatcatc tgcatcatgt ggagct 46
<210> 72
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 71
<400> 72
ccacatgatg cagatgatgc gggttatgac ggttggtg 38
<210> 73
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 73
gatcctggcc gcatgcgtgg aaagtgtggt ggccggcgag cgagct 46
<210> 74
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 73
<400> 74
cgctcgccgg ccaccacact ttccacgcat gcggccag 38
<210> 75
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 75
gatccaactg gtggtggccg ccgtatattc gtcatcagcc ggagct 46
<210> 76
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 75
<400> 76
ccggctgatg acgaatatac ggcggccacc accagttg 38
<210> 77
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 77
gatcctggca ttggagctgg accccgtggc cgagccatca tgagct 46
<210> 78
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 77
<400> 78
catgatggct cggccacggg gtccagctcc aatgccag 38
<210> 79
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 79
gatcctggcc gtgggcgtgg catccgagcc gtgatgtgta tgagct 46
<210> 80
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 79
<400> 80
catacacatc acggctcgga tgccacgccc acggccag 38
<210> 81
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 81
gatcctggca tggctattgg tatagcaacc tgaacaccac cgagct 46
<210> 82
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 81
<400> 82
cggtggtgtt caggttgcta taccaatagc catgccag 38
<210> 83
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 83
gatcctggtg gaccccgtgg atgagccatg cgtatccggt ggagct 46
<210> 84
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 83
<400> 84
ccaccggata cgcatggctc atccacgggg tccaccag 38
<210> 85
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 85
gatcctggcc gaacccgtat tggggctggt ttgcggcggt ggagct 46
<210> 86
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 85
<400> 86
ccaccgccgc aaaccagccc caatacgggt tcggccag 38
<210> 87
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 87
gatccaccag ctggcatacc tggtggtggc gtcagccgcc ggagct 46
<210> 88
<211> 38
<212> DNA
<213> Artificial
<220>
<223> 87
<400> 88
ccggcggctg acgccaccac caggtatgcc agctggtg 38
<210> 89
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 89
gatccaacgc gtggcataaa tattggtggc cgattaccaa agagct 46
<210> 90
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 89
<400> 90
ctttggtaat cggccaccaa tatttatgcc acgcgttg 38
<210> 91
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 91
gatcccatcc gaacaacgat tggagcaaag cgccgcagtt tgagct 46
<210> 92
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 91
<400> 92
caaactgcgg cgctttgctc caatcgttgt tcggatgg 38
<210> 93
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 93
gatcctggtg gaccccgcag ccgtggtgga gctttccgat tgagct 46
<210> 94
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 93
<400> 94
caatcggaaa gctccaccac ggctgcgggg tccaccag 38
<210> 95
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 95
gatcctggcc gcataccagc tggtggcaga ccccgctgac cgagct 46
<210> 96
<211> 38
<212> DNA
<213> Artificial
<220>
<223> 95
<400> 96
cggtcagcgg ggtctgccac cagctggtat gcggccag 38
<210> 97
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 97
gatcctggca tgtgaactgg gatccgatgg cgtggtatcg tgagct 46
<210> 98
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 97
<400> 98
cacgatacca cgccatcgga tcccagttca catgccag 38
<210> 99
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 99
gatccagctg gccgtggtgg accgcgtatc gtgtgcatag cgagct 46
<210> 100
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 99
<400> 100
cgctatgcac acgatacgcg gtccaccacg gccagctg 38
<210> 101
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 101
gatcctggca tagcaactgg tatcagagca ttccgcaggt ggagct 46
<210> 102
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 101
<400> 102
ccacctgcgg aatgctctga taccagttgc tatgccag 38
<210> 103
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 103
gatccggcta ttggccgtgg aaatttgaac atgcgaccgt ggagct 46
<210> 104
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 103
<400> 104
ccacggtcgc atgttcaaat ttccacggcc aatagccg 38
<210> 105
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 105
gatccgcgtg gtggccgacc acctttccgc cgtattatta tgagct 46
<210> 106
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 105
<400> 106
cataataata cggcggaaag gtggtcggcc accacgcg 38
<210> 107
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 107
gatccaaccc gtggtggagc cattattatc cgcgtagcgt ggagct 46
<210> 108
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 107
<400> 108
ccacgctacg cggataataa tggctccacc acgggttg 38
<210> 109
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 109
gatcctggcc gcataactat ccgctgaacc atagcaaccc ggagct 46
<210> 110
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 109
<400> 110
ccgggttgct atggttcagc ggatagttat gcggccag 38
<210> 111
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 111
gatccacctg ggcgcatccg ctggaaagcg attatctgcg tgagct 46
<210> 112
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 111
<400> 112
cacgcagata atcgctttcc agcggatgcg cccaggtg 38
<210> 113
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 113
gatcccatac ctattatcat gatggctggc gtctggcgcc ggagct 46
<210> 114
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 113
<400> 114
ccggcgccag acgccagcca tcatgataat aggtatgg 38
<210> 115
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 115
gatccacctt tgtgcagacc ccgctgagcc atctgattgc ggagct 46
<210> 116
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 115
<400> 116
ccgcaatcag atggctcagc ggggtctgca caaaggtg 38
<210> 117
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 117
gatcccgtgt gccgccgagc aaactgaccc gtccgccgtt tgagct 46
<210> 118
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 117
<400> 118
caaacggcgg acgggtcagt ttgctcggcg gcacacgg 38
<210> 119
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 119
gatcccatag catttatagc gtgaccccga gcaccgcgag cgagct 46
<210> 120
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 119
<400> 120
cgctcgcggt gctcggggtc acgctataaa tgctatgg 38
<210> 121
<211> 46
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 121
gatccctgaa cacccagaac catgcgccgc tgccgagcat tgagct 46
<210> 122
<211> 38
<212> DNA
<213> Artificial
<220>
<223> complementary to 121
<400> 122
caatgctcgg cagcggcgca tggttctggg tgttcagg 38
<210> 123
<211> 106
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 123
<210> 124
<211> 98
<212> DNA
<213> Artificial
<220>
<223> complementary to 123
<400> 124
<210> 125
<211> 106
<212> DNA
<213> Artificial
<220>
<223> binding peptide
<400> 125
<210> 126
<211> 98
<212> DNA
<213> Artificial
<220>
<223> complementary to 125
<400> 126
<210> 127
<211> 30
<212> DNA
<213> Artificial
<220>
<223> 5' primer for NS4
<400> 127
ttcacaggat ccactgagct cgatgcccac 30
<210> 128
<211> 30
<212> DNA
<213> artificial
<220>
<223> 3'primer for NS4
<400> 128
gatctgggct cgagccgact agtagtcgct 30
<210> 129
<211> 7
<212> PRT
<213> artificial
<220>
<223> spacer
<400> 129
preparing a carrier on which an antigen or antibody corresponding to the target antibody or antigen in said specimen respectively is immobilized;
mixing said carrier with said specimen; and
assaying the level of an immunological agglutination reaction caused by said mixing step,
wherein said antigen or antibody immobilized on said carrier is bound to said carrier via an amino acid sequence fused to said antigen or antibody and capable of binding to said carrier.
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1),
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2),
Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3),
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ ID NO 4),
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5),
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6),
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7),
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn- Trp-Tyr-Gly-Val (SEQ ID NO 8),
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-GIn (SEQ ID NO 9),
Lys-Leu-Thr-Thr-GIn-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 1.0),
Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11),
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-Pro-Trp (SEQ ID NO 12),
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-Thr-Ser-Val. (SEQ ID NO 13),
Thr-Leu-Pro-Ser-Pro-Leu-Ala-Leu-Leu-Thr-Val-His (SEQ ID NO 14),
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-Val (SEQ ID NO 15).
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser- (SEQ ID NO 16),
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17),
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18),
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19),
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20),
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21),
Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val. (SEQ ID NO 22),
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23),
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24),
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SEQ ID NO 25),
Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26),
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27),
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28),
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO 29),
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-Val (SEQ ID NO 30),
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31),
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32),
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-Arg-Ser-Val (SEQ ID NO 33),
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34),
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35),
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36),
Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37),
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38),
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39),
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40).
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1)
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2)
Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3)
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ ID NO 4)
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5)
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6)
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7)
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-Tyr-Gly-Val (SEQ ID NO 8)
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-Gln (SEQ ID NO 9)
Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 10)
Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11)
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-Pro-Trp (SEQ ID NO 12)
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-Thr-Ser-Val (SEQ ID NO 13)
Thr-Leu-Pro-Ser-Pro-Leu-Ala-Leu-Leu-Thr-Val-His (SEQ ID NO 14)
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-Val (SEQ ID NO 15)
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser (SEQ ID NO 16)
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17)
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18)
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19)
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20)
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21)
Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val (SEQ ID NO 22)
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23)
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24)
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SEQ ID NO 25)
Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26)
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27)
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28)
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO 29)
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-val (SEQ ID NO 30)
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31)
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32)
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-Arg-Ser-Val. (SEQ ID NO 33)
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34)
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35)
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36)
Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37)
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38)
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39)
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40).
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1)
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2)
Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3)
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ ID NO 4)
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5)
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6)
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7)
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-Tyr-Gly-Val (SEQ ID NO 8)
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-Gln (SEQ ID NO 9)
Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 10)
Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11)
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-Pro-Trp (SEQ ID NO 12)
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-Thr-Ser-Val (SEQ ID NO 13)
Thr-Leu-Pro-Ser-Pro-Leu-Ala-Leu-Leu-Thr-Val-His (SEQ ID NO 14)
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-val (SEQ ID NO 15)
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser (SEQ ID NO 16)
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17)
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18)
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19)
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20)
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21)
Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val (SEQ ID NO 22)
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23)
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24)
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SEQ ID NO 25)
Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26)
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27)
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28)
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO. 29).
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-Val (SEQ ID NO 30)
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31)
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32)
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-Arg-Ser-Val (SEQ ID NO 33)
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34)
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35)
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36)
Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37)
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38)
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39)
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40).
Vorbereiten eines Trägers, auf dem ein Antigen oder Antikörper entsprechend dem Zielantikörper oder -antigen in der Probe immobilisiert ist;
Mischen des Trägers mit der Probe; und
Analysieren des Ausmaßes einer durch den Mischschritt verursachten immunologischen Agglutinationsreaktion,
wobei das auf dem Träger immobilisierte Antigen oder der auf dem Träger immobilisierte Antikörper an den Träger über eine Aminosäuresequenz gebunden ist, die an das Antigen oder den Antikörper fusioniert ist und an den Träger zu binden vermag.
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1),
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2),
Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3),
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ ID NO 4),
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5),
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6),
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7),
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-Tyr-Gly-Val (SEQ ID NO 8),
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-Gln (SEQ ID NO 9),
Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 10),
Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11),
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-Pro-Trp (SEQ ID NO 12),
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-Thr-Ser-Val (SEQ ID NO 13),
Thr-Leu-Pro-Ser-Pro-Leu-Ala-Leu-Leu-Thr-Val-His (SEQ ID NO 14),
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-Val (SEQ ID NO 15).
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser (SEQ ID NO 16),
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17),
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18),
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19),
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20),
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21),
Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val (SEQ ID NO 22),
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23),
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24),
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SEQ ID NO 25),
Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26),
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27),
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28),
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO 29),
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-Val (SEQ ID NO 30),
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31),
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32),
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-Arg-Ser-Val (SEQ ID NO 33),
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34),
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35),
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36),
Thr-Phe-Val-GIn-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37),
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38),
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39),
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40).
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1),
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2),
Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3),
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ ID NO 4),
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5),
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6),
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7),
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-Tyr-Gly-Val (SEQ ID NO 8),
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-Gln (SEQ ID NO 9),
Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 10),
Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11),
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-Pro-Trp (SEQ ID NO 12),
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-Thr-Ser-Val (SEQ ID NO 13),
Thr-Leu-Pro-Ser-Pro-Leu-Ala-Leu-Leu-Thr-Val-His (SEQ ID NO 14),
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-Val (SEQ ID NO 15),
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser (SEQ ID NO 16),
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17),
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18),
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19),
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20),
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21),
Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val (SEQ ID NO 22),
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23),
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24),
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SEQ ID NO 25),
Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26),
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27),
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28),
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO 29),
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-Val (SEQ ID NO 30),
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31),
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32),
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-Arg-Ser-Val (SEQ ID NO 33),
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34),
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35),
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36),
Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37),
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38),
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39),
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40).
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1),
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2),
Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3),
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ ID NO 4),
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5),
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6),
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7),
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-Tyr-Gly-Val (SEQ ID NO 8),
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-Gln (SEQ ID NO 9),
Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 10),
Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11),
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-Pro-Trp (SEQ ID NO 12),
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-Thr-Ser-Val (SEQ ID NO 13),
Thr-Leu-Pro-Ser-Pro-Leu-Ala-Leu-Leu-Thr-Val-His (SEQ ID NO 14),
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-Val (SEQ ID NO 15),
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser (SEQ ID NO 16),
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17),
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18),
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19),
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20),
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21),
Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val (SEQ ID NO 22),
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23),
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24),
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SEQ ID NO 25),
Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26),
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27),
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28),
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO 29),
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-Val (SEQ ID NO 30),
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31),
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32),
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-Arg-Ser-Val (SEQ ID NO 33),
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34),
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35),
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36),
Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37),
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38),
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39),
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40).
préparer un support sur lequel un antigène ou anticorps correspondant à l'anticorps ou à l'antigène cible présent dans ledit échantillon, respectivement, est immobilisé ;
mélanger ledit support avec ledit échantillon ; et
analyser le degré d'une réaction d'agglutination immunologique provoquée par ladite étape de mélange ;
dans laquelle ledit antigène ou anticorps immobilisé sur ledit support est lié audit support par l'intermédiaire d'une séquence d'aminoacides fusionnée audit antigène ou anticorps et capable de se lier audit support.
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1),
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2),
Lys-cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3),
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ ID NO 4),
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5),
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6),
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7),
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-Tyr-Gly-Val (SEQ ID NO 8),
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-Gln (SEQ ID NO 9),
Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 10),
Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11),
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-Pro-Trp (SEQ ID NO 12),
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-Thr-Ser-Val (SEQ ID NO 13),
Thr-Leu-Pro-Ser-Pro-Leu-Ala-Leu-Leu-Thr-Val-His (SEQ ID NO 14),
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-Val (SEQ ID NO 15).
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser (SEQ ID NO 16),
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17),
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18),
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19),
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20),
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21),
Trp-Pro-Asn-pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val (SEQ ID NO 22),
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23),
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24),
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SEQ ID NO 25),
Trp-Trp-Thr-pro-Gln-pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26),
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27),
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28),
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO 29),
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-Val (SEQ ID NO 30),
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31),
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32),
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-Arg-Ser-Val (SEQ ID NO 33),
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34),
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35),
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36),
Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37),
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38),
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39),
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40).
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1)
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2)
Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3)
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ ID NO 4)
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5)
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6)
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7)
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-Tyr-Gly-Val (SEQ ID NO 8)
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-Gln (SEQ ID NO 9)
Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 10)
Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11)
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-Pro-Trp (SEQ ID NO 12)
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ale-Val-Thr-Ser-Val (SEQ ID NO 13)
Thr-Leu-Pro-ser-Pro-Leu-Ala-Leu-Leu-Thr-Val-His (SEQ ID NO 14)
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-Val (SEQ ID NO 15)
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-Ser (SEQ ID NO 16)
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17)
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18)
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19)
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20)
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21)
Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val (SEQ ID NO 22)
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23)
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24)
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SFQ ID NO 25)
Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26)
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27)
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28)
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO 29)
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-Val (SEQ ID NO 30)
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31)
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32)
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr--Pro-Arg-Ser-Val (SEQ ID NO 33)
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34)
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35)
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36)
Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37)
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38)
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39)
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40).
Lys-Tyr-Asp-Ser-Arg-His-Leu-His-Thr-His-Ser-His (SEQ ID NO 1)
Pro-Asn-Arg-Leu-Gly-Arg-Arg-Pro-Val-Arg-Trp-Glu (SEQ ID NO 2)
Lys-Cys-Cys-Tyr-Tyr-Asp-His-Ser-His-Ala-Leu-Ser (SEQ ID NO 3)
Glu-Tyr-Leu-Ser-Ala-Ile-Val-Ala-Gly-Pro-Trp-Pro (SEQ I D NO 4)
Lys-Leu-Trp-Ile-Leu-Glu-Pro-Thr-Val-Thr-Pro-Thr (SEQ ID NO 5)
Gln-Ser-Asn-Leu-Lys-Val-Ile-Pro-Ser-Trp-Trp-Phe (SEQ ID NO 6)
Trp-Ile-Pro-Pro-Gln-Trp-Ser-Arg-Leu-Ile-Glu-Pro (SEQ ID NO 7)
Asp-His-Pro-Gln-Ala-Lys-Pro-Asn-Trp-Tyr-Gly-Val (SEQ ID NO 8)
Gly-Leu-Pro-Pro-Tyr-Ser-Pro-His-Arg-Leu-Ala-Gln (SEQ ID NO 9)
Lys-Leu-Thr-Thr-Gln-Tyr-Met-Ala-Arg-Ser-Ser-Ser (SEQ ID NO 10)
Lys-Val-Trp-Met-Leu-Pro-Pro-Leu-Pro-Gln-Ala-Thr (SEQ ID NO 11)
Asn-Val-Thr-Ser-Thr-Ala-Phe-Ile-Asp-Thr-pro-Trp (SEQ ID NO 12)
Arg-Leu-Asn-Leu-Asp-Ile-Ile-Ala-Val-Thr-Ser-Val (SEQ ID NO 13)
Thr-Leu-pro-Ser-Pro-Leu-P-la-teu-Leu-Thr-Val-His (SEQ ID NO 14)
Thr-Asn-Arg-His-Asn-Pro-His-His-Leu-His-His-Val (SEQ ID NO 15)
Trp-Pro-His-Ala-Trp-Lys-Val-Trp-Trp-Pro-Ala-ser (SEQ ID NO 16)
Asn-Trp-Trp-Trp-Pro-Pro-Tyr-Ile-Arg-His-Gln-Pro (SEQ ID NO 17)
Trp-His-Trp-Ser-Trp-Thr-Pro-Trp-Pro-Ser-His-His (SEQ ID NO 18)
Trp-Pro-Trp-Ala-Trp-His-Pro-Ser-Arg-Asp-Val-Tyr (SEQ ID NO 19)
Trp-His-Gly-Tyr-Trp-Tyr-Ser-Asn-Leu-Asn-Thr-Thr (SEQ ID NO 20)
Trp-Trp-Thr-Pro-Trp-Met-Ser-His-Ala-Tyr-Pro-Val (SEQ ID NO 21)
Trp-Pro-Asn-Pro-Tyr-Trp-Gly-Trp-Phe-Ala-Ala-Val (SEQ ID NO 22)
Thr-Ser-Trp-His-Thr-Trp-Trp-Trp-Arg-Gln-Pro-Pro (SEQ ID NO 23)
Asn-Ala-Trp-His-Lys-Tyr-Trp-Trp-Pro-Ile-Thr-Lys (SEQ ID NO 24)
His-Pro-Asn-Asn-Asp-Trp-Ser-Lys-Ala-Pro-Gln-Phe (SEQ ID NO 25)
Trp-Trp-Thr-Pro-Gln-Pro-Trp-Trp-Ser-Phe-Pro-Ile (SEQ ID NO 26)
Trp-Pro-His-Thr-Ser-Trp-Trp-Gln-Thr-Pro-Leu-Thr (SEQ ID NO 27)
Trp-His-Val-Asn-Trp-Asp-Pro-Met-Ala-Trp-Tyr-Arg (SEQ ID NO 28)
Ser-Trp-Pro-Trp-Trp-Thr-Ala-Tyr-Arg-Val-His-Ser (SEQ ID NO 29)
Trp-His-Ser-Asn-Trp-Tyr-Gln-Ser-Ile-Pro-Gln-Val (SEQ ID NO 30)
Gly-Tyr-Trp-Pro-Trp-Lys-Phe-Glu-His-Ala-Thr-Val (SEQ ID NO 31)
Ala-Trp-Trp-Pro-Thr-Thr-Phe-Pro-Pro-Tyr-Tyr-Tyr (SEQ ID NO 32)
Asn-Pro-Trp-Trp-Ser-His-Tyr-Tyr-Pro-Arg-Ser-Val (SEQ ID NO 33)
Trp-Pro-His-Asn-Tyr-Pro-Leu-Asn-His-Ser-Asn-Pro (SEQ ID NO 34)
Thr-Trp-Ala-His-Pro-Leu-Glu-Ser-Asp-Tyr-Leu-Arg (SEQ ID NO 35)
His-Thr-Tyr-Tyr-His-Asp-Gly-Trp-Arg-Leu-Ala-Pro (SEQ ID NO 36)
Thr-Phe-Val-Gln-Thr-Pro-Leu-Ser-His-Leu-Ile-Ala (SEQ ID NO 37)
Arg-Val-Pro-Pro-Ser-Lys-Leu-Thr-Arg-Pro-Pro-Phe (SEQ ID NO 38)
His-Ser-Ile-Tyr-Ser-Val-Thr-Pro-Ser-Thr-Ala-Ser (SEQ ID NO 39)
Leu-Asn-Thr-Gln-Asn-His-Ala-Pro-Leu-Pro-Ser-Ile (SEQ ID NO 40).
REFERENCES CITED IN THE DESCRIPTION
Patent documents cited in the description
Non-patent literature cited in the description